First, we showed that, compared to control VV, IL-36γ-VV greatly enhanced tumor site adaptive immune responses by increasing the tumor infiltration of CD3+ T lymphocytes, including both CD4+ and CD8+ T cells. The gene discussed is IL36G; the disease is neoplasm.